The Lancet: June 22, 2007

Matthew During, author of a phase I study of gene therapy in the treatment of Parkinson's disease dicusses the study, designed to assess safety and tolerability, shows encouraging early results for the treatment of Parkinson's disease and other neurodegenerative disorders. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://you...

Om Podcasten

Jessamy Bagenal, Chloe Wilson, and Callum Davidson—editors at The Lancet—and Gavin Cleaver, The Lancet Group’s Audio Producer, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.